Key result
Ticagrelor-based triple therapy leads to severe intracranial hemorrhage within 3 days post-PCI.
Why the study?
Ticagrelor increases the risk of intracranial bleeding, which may be further enhanced in triple therapy for patients with atrial fibrillation and coronary artery disease requiring PCI.
Is ticagrelor safe as part of triple therapy in patients with atrial fibrillation and coronary artery disease requiring PCI?
Case Report (n=1)
No
Is ticagrelor safe as part of triple therapy in patients with atrial fibrillation and coronary artery disease requiring PCI?
This case report and literature review explores the safety of using ticagrelor as part of triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI.
Answers are grounded in this paper and cite their sources.
May signal elevated bleeding risk with ticagrelor triple therapy post-PCI; leaves optimal regimen open for prospective trials in AF.
Patients with atrial fibrillation who have concurrent coronary artery disease requiring percutaneous coronary intervention are subsequently prescribed dual antiplatelet therapy and anticoagulation resulting in triple therapy (TT). Ticagrelor, a reversibly binding P2Y12 antiplatelet agent, has shown superiority to clopidogrel in prevention of ischemic events and death, but is also associated with a small increase in the incidence of intracranial bleeding. This bleeding risk may be enhanced in the setting of TT. The objective of this report is to describe a case of a 70-year-old male prescribed TT with ticagrelor and to review the current literature on the safety of ticagrelor as a part of TT.
No takes yet. Share an insight, caveat, or question.
Mohammad U. Farooq (2020) conducted a case report in Atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention (n=1). Triple therapy with ticagrelor, aspirin, and apixaban was evaluated on Intracranial hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: